HTB

COVID-19: INVESTIGATIONAL DRUGS

No benefit from hydroxychloroquine, with or without macrolide antibiotics in analysis of 96,000 patients

Remdesivir improves recovery time in early COVID-19 infection: first definitive results of benefit

Remdesivir for COVID-19: randomised study shows similar antiviral effect to placebo

Other remdesivir news: top results from NIH and Gilead studies – emergency approval in US and Japan

Potential for tocilizumab to treat moderate to severe COVID-19

Detectable viral load and IL-6: a role for tocilizumab or anti-JAK inhibitor baricitinib?

Rheumatoid arthritis drug anakinra in small study to treat COVID-19

Anticoagulants associated with improved survival rates in people hospitalised with COVID-19

Monoclonal antibodies identified in convalescent plasma COVID-19

Studies reporting lack of benefit from hydroxychloroquine to treat COVID-19

Israeli cohort shows no protection against COVID-19 from childhood BCG vaccination

Remdesivir for COVID-19: first results from compassionate access programme

No benefit of hydroxychloroquine and azithromycin in people hospitalised with COVID-19

High-dose chloroquine study for COVID-19 stopped with worse outcomes: high risk of cardiovascular events

Gilead expand UK sites for two phase-3 studies of remdesivir to treat COVID-19

Early drugs being studied for COVID-19